Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReadyfusOR is a ready-to-use, pre-filled infusion system developed by BioQ Pharma for the management of post-surgical pain. It utilizes the invenious™ connect-and-go technology, which integrates the non-narcotic local anesthetic ropivacaine hydrochloride (0.2%) into a disposable, single-use, self-contained administration device. The system is designed to provide continuous peripheral nerve block or wound site infusion for at least 48 hours post-surgery. Ropivacaine acts as a local anesthetic by reversibly blocking voltage-gated sodium channels in nerve fibers, thereby inhibiting the conduction of nerve impulses. This product aims to reduce medication errors and manual compounding while serving as an opioid-sparing therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ReadyfusOR.